Electromed (NYSE American: ELMD) Stock Analysis: Price Target Raised Despite Sharp Decline

• Freedom Broker raised its price target for Electromed (NYSE American: ELMD) from $45 to $50 while maintaining a Buy rating.
• Electromed reported record fiscal fourth-quarter earnings of $0.39 per diluted share, beating the Zacks Consensus Estimate of $0.32 by 21.88%.
• Quarterly revenue increased 11.6% to $19.42 million but missed the Zacks estimate by 2.43%.
• Electromed shares fell sharply following the results and news of CEO Jim Cunniff’s planned retirement.

Electromed (NYSE American: ELMD) develops, manufactures, and sells airway-clearance devices for patients with compromised pulmonary function. Its main product is the SmartVest Airway Clearance System.

On August 26, 2026, Freedom Broker analyst Ilya Zubkov raised Electromed’s price target from $45 to $50 while maintaining a Buy rating. Based on an intraday share price of $32.20, the target implied potential upside of approximately 55.28%. Analyst report

Electromed reported record fiscal fourth-quarter earnings of $0.39 per diluted share, up from $0.25 a year earlier and above the Zacks Consensus Estimate of $0.32. Quarterly net revenue increased 11.6% to $19.42 million, compared with $17.39 million in the prior-year quarter. However, revenue missed the Zacks estimate by 2.43%.

For the full fiscal year, revenue increased 15.3% to $73.8 million, while net income rose to $11.3 million, or $1.30 per diluted share. The company also ended the year with $20.5 million in cash and no outstanding debt.

Despite the strong earnings growth, Electromed shares fell approximately 18.15% to $32.20 during trading on August 26. The decline followed the modest revenue miss and the announcement that CEO Jim Cunniff plans to retire in April 2027. At that price, Electromed had a market capitalization of approximately $266.6 million. Its 52-week trading range was approximately $23.01 to $47.40.